Abstract |
We have investigated the effect of therapy for Helicobacter pylori gastritis on serum concentrations of pepsinogen I and II in 43 patients. In the 22 patients in whom therapy resulted in dramatic decrease in gastritis scores and in clearance of the bacteria, there was a highly significant (P = 0.0001) fall in mean serum pepsinogen II from 13.3 +/- 0.8 to 7.9 +/- 0.7 micrograms/liter, and a less pronounced fall in pepsinogen I from 89.0 +/- 5.9 to 78.5 +/- 0.4 micrograms/liter (P = 0.01). These changes resulted in a significant (P = 0.01) increase in the pepsinogen I/II ratio. In contrast, nonsignificant declines of 3.5% and 11.6% were observed in mean pepsinogen I and II levels in the 21 patients whose gastritis failed to resolve histologically and whose infection did not clear. These findings suggest that serum pepsinogen levels, especially pepsinogen II, are a new tool that may be found to be clinically useful in evaluation of treatment outcome in patients with H. pylori-associated gastritis.
|
Authors | F M Hunter, P Correa, E Fontham, B Ruiz, M Sobhan, I M Samloff |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 38
Issue 11
Pg. 2081-6
(Nov 1993)
ISSN: 0163-2116 [Print] United States |
PMID | 8223084
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Organometallic Compounds
- Pepsinogens
- Salicylates
- Metronidazole
- bismuth subsalicylate
- Nitrofurantoin
- Bismuth
|
Topics |
- Adult
- Biopsy
- Bismuth
(therapeutic use)
- Female
- Gastric Mucosa
(pathology)
- Gastritis
(drug therapy, microbiology)
- Helicobacter Infections
(blood, diagnosis, drug therapy)
- Helicobacter pylori
(isolation & purification)
- Humans
- Male
- Metronidazole
(therapeutic use)
- Middle Aged
- Nitrofurantoin
(therapeutic use)
- Organometallic Compounds
(therapeutic use)
- Pepsinogens
(blood)
- Salicylates
(therapeutic use)
|